Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma

Endocrine-Related Cancer

Volumn 13, Issue 3, 2006, Pages 839-849

  Fritzsche, S ^a   Kenzelmann, M ^b   Hoffmann, M J ^a   Muller M ^a   Engers, R ^a   Grone H J ^b   Schulz, W A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN SPRY 1; PROTEIN SPRY 2; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER TISSUE; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; FETUS (ANATOMY); FOLLOW UP; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; MICRODISSECTION; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; DNA PRIMERS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 33751115512     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01190     Document Type: Article

References (28)

1. Blackledge G 2003 Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy. Journal of Uroloy 170 77-83.
2. Bloethner S, Chen B, Hemminki K, Müller-Berghaus J, Ugurel S, Schadendorf D & Kumar R 2005 Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 26 1224-1232.
3. Chen ZX & Riggs AD 2005 Maintenance and regulation of DNA methylation patterns in mammals. Biochemistry & Cell Biology 83 438-448.
4. Chi L, Zhang S, Lin Y, Prunskaite-Hyyryläinen R, Vuolteenaho R, Itäranta P, Prunskaite-Hyyryläinen R, Vuolteenaho R, Itäranta P et al. 2004 Sprouty proteins regulate ureteric branching by coordinating reciprocal epithelial Wnt11, mesenchymal Gdnf and stromal Fgf7 signalling during kidney development. Development 131 3345-3356.
5. Chomczynski P & Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 162 156-159.
6. Christofori G 2003 Split personalities: the agonistic antagonist Sprouty. Nature Cell Biology 5 377-379.
7. Cohen CD, Gröne H-J, Gröne EF, Nelson PJ, Schlöndorff D & Kretzler M 2002 Laser microdissection and gene expression analysis on formaldehyde-fixed archival tissue. Kidney International 61 125-132.
8. Cronauer MV, Schulz WA, Seifert HH, Ackermann R & Burchardt M 2003 Fibroblast growth factors and their receptors in urological cancers: Basic research and clinical implications. European Urology 43 309-319.
9. Cui X & Churchill GA 2003 Statistical tests for differential expression in cDNA microarray experiments. Genome Biology 4 210.
10. Djakiew D 2000 Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 42 150-160.
11. Egan JE, Hall A, Yatsula BA & Bar-Sagi D 2002 The bimodal regulation of epidermal growth factor signalling by human sprouty proteins. PNAS 9 6041-6046.
12. Florl AR, Steinhoff C, Müller M, Seifert HH, Hader C, Engers R, Ackermann R & Schulz WA 2004 Coordinate hypermethylation at specific sites in prostate carcinoma precedes LINE-1 hypomethylation. British Journal of Cancer 91 985-994.
13. Gross I, Bassit B, Benezra M & Licht JD 2001 Mammalian Sprouty proteins inhibit cell growth and differentiation by preventing Ras activation. Journal of Biological Chemistry 276 46460-46468.
14. Hacohen N, Kramer S, Sutherland D, Hiromi Y & Krasnow MA 1998 Sprouty encodes a novel antagonist of FGF signalling that patterns apical branching of the Drosophila airways. Cell 92 253-263.
15. Hanafusa H, Torii S, Yasunaga T & Nishida E 2002 Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nature Cell Biology 4 850-858.
16. Hoffmann M, Florl A, Seifert HH & Schulz WA 2005 Multiple mechanisms downregulate CDKN1C in human bladder cancer. International Journal of Cancer 114 406-413.
17. Kang GH, Lee S, Lee HJ & Hwang KS 2004 Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. Journal of Pathology 202 233-240.
18. Kenzelmann M, Klaren R, Hergenhahn M, Bonrouhi M, Grone HJ, Schmid W & Schutz G 2004 High-accuracy amplification of nanogram total RNA amounts for gene profiling. Genomics 83 550-558.
19. Kwabi-Addo B, Ozen M & Ittmann M 2004a The role of fibroblast growth factors and their receptors in prostate cancer. Endocrine-Related Cancer 11 709-724.
20. Kwabi-Addo B, Wang J, Erdem H, Vaid A, Castro P, Ayala G & Ittmann M 2004b The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Research 64 4728-4735.
21. Li X, Brunton V, Burgar H, Wheldon L & Heath J 2004 FRS2-dependent SRC activation is required for fibroblast growth factor receptor-induced phosphorylation of Sprouty and suppression of ERK activity. Journal of Cell Science 117 6007-6017.
22. Lo T, Yusoff P, Fong CW, Quo K, McCaw BJ, Phillips WA, Yang H, Wong ES, Leong HF, Zeng Q et al. 2004 The Ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, Sprouty 1 and Sprouty 2 are deregulated in breast cancer. Cancer Research 64 6127-6136.
23. McKie A, Douglas D, Olijslaers S, Graham J, Omar M, Heer R, Gnanapragasam V, Robson C & Leung H 2005 Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene 24 2166-2174.
24. Swiatkowski S, Seifert HH, Steinhoff C, Prior A, Thievessen I, Schliess F & Schulz WA 2003 Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Experimental Cell Research 282 48-57.
25. Wang L, Ji C, Wu H, Xu J, Wu Q, Dai J, Yin G, Ye X, Gu S & Xie Y 2003 Identification and expression analysis of a novel splice variant of human Sprouty 1 gene. International Journal of Molecular Medicine 12 783-787.
26. Wong E, Fong C, Lim J, Yusoff P, Low B, Langdon W & Guy G 2002 Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO Journal 21 4796-4808.
27. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB & Nelson WG 2004 Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Research 64 1975-1986.
28. Yusoff P, Lao D, Ong S, Wong E, Lim J, Lo T, Leong H, Fong C & Guy G 2002 Sprouty2 inhibits the Ras/MAP Kinase pathway by inhibiting the activation of Raf. Journal of Biological Chemistry 277 3195-3201.